Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dose of Indomethacin Suppository for Preventing Post-ERCP Pancreatitis
NCT06031363Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: serum amylase concentration. Started Nov 2022; status: completed.
02
Drugs
indomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT06031363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031363.